Bibliographic information

GuidelineWHO Guidelines for malaria, 14 March 2023
Year of Publication2023
Issuing InstitutionWHO

Recommendation

Maintained

Short-course standard dose primaquine treatment: To prevent relapse, an additional treatment option of using primaquine 0.5 mg/kg/day for seven days is recommended to treat P. vivax or P. ovale malaria in children and adults (except pregnant women, infants aged < 6 months, women breastfeeding infants aged < 6 months, women breastfeeding older infants unless they are known not to be G6PD deficient, and people with G6PD deficiency).

Recommended in favor

Strong

Also Featured In

This recommendation also appears in the following guidelines:

Originally Developed
Guideline

WHO guidelines for malaria, 25 November 2022.

Year2022
InstitutionWorld Health Organization